PRODUCT THEATERS

Product Theaters feature exhibitor presentations on new research findings and products to small groups of annual meeting attendees (no more than 150) and are located on the second level of the Orange County Convention Center, directly across from the Exhibit Hall. The Product Theater sessions will be solely promotional in nature; therefore, continuing medical education credits will not be offered. ASH will provide lunch during each theater. Please bring your Sunday and/or Monday Exhibit Hall lunch ticket to the applicable Product Theater.

Saturday, December 7
11:30 a.m.-12:30 p.m.

Sponsored by: Genentech

New longer-term 48-month data for the only chemo-free regimens in CLL with fixed treatment duration

Speaker: Kathryn Humphrey, Associate Clinical Science Director & Global Development Lead, Venetoclax CLL/NHL Genentech

Product Theater 1 - Room 209AB

Sponsored by: Astellas

XOSPATA (gilteritinib): A Targeted Therapeutic Approach for Relapsed/Refractory FLT3m+ AML Patients

Speaker: Erkut Bahcecici, MD, Vice President of Medical Science-Hematology, Pharma Global Development, Astellas

Product Theater 2 - Room 208AB

Sponsored by: Celgene

Discover the Role of Two Immunotherapies in Multiple Myeloma

Speaker: Amit Agarwal, MD, PhD, Disease Lead, Multiple Myeloma, U.S. Medical Affairs, Celgene

Product Theater 3 - Room 207BC

This presentation is intended for U.S.-based registered Meeting attendees

Sponsored by: Sanofi Genzyme

A Breakthrough in aTTP Treatment

Speaker: Rui Sousa, Head of Global Medical TTP, Sanofi Genzyme

Product Theater 4 - Room 204BC

Sponsored by: Amgen

The BiTE® Immuno-Oncology Platform and Emerging Targets in Hematologic Malignancies

Speaker: Byeong Yoon, PhD, Executive Director, Oncology Global Medical Affairs, Amgen

Product Theater 5 - Room 203AB

This presentation is intended for registered Meeting attendees only

Sponsored by: Pfizer

A Discussion of Efficacy and Safety on a Treatment Option for Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Speaker: Fernando Vargas, MD, Medical Director, U.S. Medical Affairs, Hematology, Pfizer

Product Theater 6 - Room 202AB

This presentation is intended for U.S.-based attendees only

Sunday, December 8
11:30 a.m.-12:30 p.m.

Sponsored by: Genentech

Considerations for Tailoring First-line Follicular Lymphoma Treatment

Speaker: Joana Parreira, MD, Global Medical Director, Hematology, F. Hoffmann-La Roche

Product Theater 1 - Room 209AB

Sponsored by: Stemline Therapeutics, Inc.

The Only Approved Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Speaker: Edwin DeWitt, MD, Medical Affairs, Stemline Therapeutics, Inc.

Product Theater 2 - Room 208AB

As of November 13, 2019.

Please see other side for additional Product Theater information
Sunday, December 8, 11:30 a.m.-12:30 p.m. continued

Sponsored by: Celgene
The Role a new combination therapy in Previously Treated Follicular Lymphoma
Speaker: Mecide Gharibo, MD, Senior Medical Director, U.S. Medical Affairs, Celgene
Product Theater 3 - Room 207BC
This presentation is intended for U.S.-based registered Meeting attendees

Sponsored by: Alexion Pharmaceuticals, Inc.
Clinical Development in Complement Inhibition: ULTOMIRIS® (ravulizumab-cwvz) for the Treatment of atypical-HUS and PNH
Speakers:
Lance Trainor, MD, Senior Director, Scientific Affairs, Alexion Pharmaceuticals
Yogesh Patel, PharmD, MBA, Senior Medical Director, U.S. Medical Affairs Complement Franchise, Alexion Pharmaceuticals
Product Theater 4 - Room 204BC

Sponsored by: Agios Pharmaceuticals
Case Study: A 19-Year-Old Female with Anemia and Distal Radius Fracture
Speaker: Karen Anderson, Senior Director, Medical Affairs, Agios Pharmaceuticals, Inc.
Product Theater 5 - Room 203AB

Sponsored by: Pfizer
A Discussion on Efficacy and Safety of a Non-Intensive Treatment Option for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML)
Speaker: Paul D’Amico, PhD, RN, NP, Medical Director, U.S. Medical Affairs, Hematology, Pfizer
Product Theater 6 - Room 202AB
This presentation is intended for U.S.-based attendees only

Monday, December 9
12:15 p.m.-1:15 p.m.

Sponsored by: Genentech
A new FDA-approved therapeutic option for R/R DLBCL: study results from a randomized trial
Speaker: Jamie Hirata, PharmD, Global Development Leader, Genentech
Product Theater 1 - Room 209AB
This presentation is intended for U.S.-based registered Meeting attendees

Sponsored by: GSK
Advances in targeting of B-Cell Maturation Antigen (BCMA) as a novel therapeutic approach in Multiple Myeloma
Speakers:
Scott Miller, PhD, Hematology Scientific Director, U.S. Medical Affairs Oncology, GSK
Emma Scott, MD, Hematology Medical Expert, U.S. Medical Affairs Oncology, GSK
Product Theater 2 - Room 208AB
This presentation is intended for U.S.-based registered Meeting attendees

Sponsored by: Celgene
A New Treatment Option for adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
Speaker: Robert Peter Gale MD, PhD, DSc(hc), FACP, FRCP, FRCPI(hon), FRSM, Executive Medical Director, Clinical R&D, Celgene
Product Theater 6 - Room 202AB
This presentation is intended for U.S.-based registered Meeting attendees

Sponsored by: AstraZeneca
Acalabrutinib in B Cell Malignancies
Speakers:
Mostafa Elhamy, Global Development Lead, AstraZeneca
Cheng Quah, Senior Medical Director, AstraZeneca
Product Theater 4 - Room 204BC
This presentation is intended for U.S.-based attendees only

Sponsored by: AbbVie
VENCLEXTA®, a BCL-2 inhibitor for first-line AML: FDA approved regardless of mutational status
Speaker: Rod Humerickhouse, MD, PhD, TA Lead - Hematology, U.S. Medical Affairs, AbbVie
Product Theater 5 - Room 203AB
This presentation is intended for U.S.-based registered Meeting attendees

As of November 13, 2019.
Please see other side for additional Product Theater information